{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:55:03Z","timestamp":1792641303693,"version":"4.5.0"},"reference-count":25,"publisher":"Japan Endocrine Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1507\/endocrj.ej20-0159","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T22:08:22Z","timestamp":1595369302000},"page":"1169-1177","source":"Crossref","is-referenced-by-count":6,"title":["Changes in cardiovascular risk factors in patients with acromegaly after trans-sphenoidal adenomectomy"],"prefix":"10.1507","volume":"67","author":[{"given":"Yu-Shu","family":"Yen","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harn-Shen","family":"Chen","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan"},{"name":"Division of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119: 3189\u20133202.","DOI":"10.1172\/JCI39375"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Wu TE, Lin HD, Lu RA, Wang ML, Chen RL, et al. (2010) The role of insulin-like growth factor-1 and growth hormone in the mortality of patients with acromegaly after trans-sphenoidal surgery. Growth Horm IGF Res 20: 411\u2013415.","DOI":"10.1016\/j.ghir.2010.09.003"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Fazio S, Cittadini A, Biondi B, Palmieri EA, Riccio G, et al. (2000) Cardiovascular effects of short-term growth hormone hypersecretion. J Clin Endocrinol Metab 85: 179\u2013182.","DOI":"10.1210\/jcem.85.1.6313"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Mosca S, Paolillo S, Colao A, Bossone E, Cittadini A, et al. (2013) Cardiovascular involvement in patients affected by acromegaly: an appraisal. Int J Cardiol 167: 1712\u20131718.","DOI":"10.1016\/j.ijcard.2012.11.109"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP (2008) Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 93: 61\u201367.","DOI":"10.1210\/jc.2007-1191"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Holdaway IM, Bolland MJ, Gamble GD (2008) A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159: 89\u201395.","DOI":"10.1530\/EJE-08-0267"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Colao A, Pivonello R, Grasso LFS, Auriemma RS, Galdiero M, et al. (2011) Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. Eur J Endocrinol 165: 713\u2013721.","DOI":"10.1530\/EJE-11-0408"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Bogazzi F, Battolla L, Spinelli C, Rossi G, Gavioli S, et al. (2007) Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J Clin Endocrinol Metab 92: 4271\u20134277.","DOI":"10.1210\/jc.2007-1213"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Akutsu H, Kreutzer J, Wasmeier G, Ropers D, Rost C, et al. (2010) Acromegaly per se does not increase the risk for coronary artery disease. Eur J Endocrinol 162: 879\u2013886.","DOI":"10.1530\/EJE-09-0945"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Cannavo S, Almoto B, Cavalli G, Squadrito S, Romanello G, et al. (2006) Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography. J Clin Endocrinol Metab 91: 3766\u20133772.","DOI":"10.1210\/jc.2005-2857"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11 Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, et al. (2014) 2013 ACC\/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Circulation 129 (suppl 2): S1\u2013S45.","DOI":"10.1161\/01.cir.0000437738.63853.7a"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 M\u00f8ller N, J\u00f8rgensen JO (2009) Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 30:152\u2013177.","DOI":"10.1210\/er.2008-0027"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Frara S, Maffezzoni F, Mazziotti G, Giustina A (2016) Currents and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol Metab 27: 470\u2013483.","DOI":"10.1016\/j.tem.2016.04.014"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, et al. (2000) Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 52: 549\u2013555.","DOI":"10.1046\/j.1365-2265.2000.00986.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Hansen TK, Moller J, Thomsen K, Frandsen E, Dall R, et al. (2001) Effects of growth hormone on renal tubular handling of sodium in healthy humans. Am J Physiol Endocrinol Metab 281: E1326\u2013E1332.","DOI":"10.1152\/ajpendo.2001.281.6.E1326"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Moller J, Jorgensen JO, Marqversen J, Frandsen E, Christiansen JS (2000) Insulin-like growth factor I administration induces fluid and sodium retention in healthy adults: possible involvement of renin and atrial natriuretic factor. Clin Endocrinol 52: 181\u2013186.","DOI":"10.1046\/j.1365-2265.2000.00931.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Rizzoni D, Porteri E, Giustina A, De Ciuceis C, Sleiman I, et al. (2004) Acromegalic patients show the presence of hypertrophic remodeling of subcutaneous small resistance arteries. Hypertension 43: 561\u2013565.","DOI":"10.1161\/01.HYP.0000114604.52270.95"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18 Tan KC, Shiu SW, Janus ED, Lam KS (1997) LDL subfractions in acromegaly: relation to growth hormone and insulin-like growth factor-I. Atherosclerosis 129: 59\u201365.","DOI":"10.1016\/S0021-9150(96)06015-7"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19 Nikkila EA, Pelkonen R (1975) Serum lipids in acromegaly. Metabolism 24: 829\u2013838.","DOI":"10.1016\/0026-0495(75)90129-8"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Hainer V, Zak A, Sindelkova E, Wernischova V, Belikovova H, et al. (1985) Elevation of high density lipoproteins in acromegalics after lisuride treatment. Horm Metab Res 17: 220\u2013221.","DOI":"10.1055\/s-2007-1013498"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Carmichael JD, Broder MS, Cherepanov D, Chang E, Mamelak A, et al. (2017) The association between biochemical control and cardiovascular risk factors in acromegaly. BMC Endocr Disord 17: 15.","DOI":"10.1186\/s12902-017-0166-6"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22 Briet C, Ilie MD, Kuhn E, Maione L, Brailly-Tabard S, et al. (2019) Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bic\u00eatre cohort, and review of the literature. Endocrine 63: 348\u2013360.","DOI":"10.1007\/s12020-018-1797-8"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Kamenick\u00fd P, Mazziotti G, Lomb\u00e8s M, Giustina A, Chanson P (2014) Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications. Endocr Rev 35: 234\u2013281.","DOI":"10.1210\/er.2013-1071"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Auriemma RS, Galdiero M, De Martino MC, De Leo M, Grasso LF, et al. (2010) The kidney in acromegaly: renal structure and function in patients with acromegaly during active disease and 1 year after disease remission. Eur J Endocrinol 162: 1035\u20131042.","DOI":"10.1530\/EJE-10-0007"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Kamenicky P, Blanchard A, Frank M, Salenave S, Letierce A, et al. (2011) Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity. J Clin Endocrinol Metab 96: 2127\u20132135.","DOI":"10.1210\/jc.2011-0078"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/67\/12\/67_EJ20-0159\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T03:43:17Z","timestamp":1609558997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/67\/12\/67_EJ20-0159\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej20-0159","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}